o Improvement of gross margin by +33%, to €5m
o 15% reduction in operational loss
o Improved net income from continuing operations by 23%
o Reinforcement of Sanyou Medical in the capital of Implanet up to 43.14%, through the exercise of all of its BSAs at €0.32 per share
Bordeaux, Boston, March 7, 2023 – 6:00 p.m. CET: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and in the distribution of technological medical equipment, announces its results for the fiscal year ended December 31, 2022 and approved by the Board of Directors on March 7, 2023.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]